Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate
- Ulrich Joimel1Email author,
- Caroline Gest1,
- Jeannette Soria2, 3,
- Linda-Louise Pritchard4,
- Jérôme Alexandre2, 5,
- Marc Laurent1,
- Emmanuel Blot1,
- Lionel Cazin1,
- Jean-Pierre Vannier1,
- Rémi Varin1,
- Hong Li†1 and
- Claudine Soria†1
© Joimel et al; licensee BioMed Central Ltd. 2010
Received: 7 October 2009
Accepted: 17 July 2010
Published: 17 July 2010
Infiltration by macrophages (Mφ) indicates a poor prognosis in breast cancers, in particular by inducing angiogenesis. Our study aimed 1) to investigate the mechanism by which cooperation between Mφ and aggressive breast cancer cells (MDA-MB-231) induces angiogenesis; 2) to examine the effect of tetrathiomolybdate (TM) on this angiogenic activity.
Mφ coincubated with MDA-MB-231 were used as a model to mimic the inflammatory microenvironment. Angiogenesis induced by the culture media was tested in the chick chorioallantoic membrane (CAM). Mφ phenotype was evaluated by 1) expression of the M1 marker CD80, and secretion of interleukin 10 (IL-10), an M2 marker; 2) capacity to secrete Tumour Necrosis Factor α (TNFα) when stimulated by lipopolysaccharide/interferon γ (LPS/IFNγ); 3) ability to induce MDA-MB-231 apoptosis. To explore the molecular mechanisms involved, cytokine profiles of conditioned media from MDA-MB-231, Mφ and the coculture were characterised by an antibody cytokine array. All experiments were carried out both in presence and in absence of TM.
Incubation of Mφ with MDA-MB-231 induced a pro-angiogenic effect in the CAM. It emerged that the angiogenic activity of the coculture is due to the capacity of Mφ to switch from M1 Mφ towards M2, probably due to an increase in Macrophage Colony Stimulating Factor. This M1-M2 switch was shown by a decreased expression of CD80 upon LPS/IFNγ stimulation, an increased secretion of IL-10, a decreased secretion of TNFα in response to LPS/IFNγ and an inability to potentiate apoptosis. At the molecular level, the angiogenic activity of the coculture medium can be explained by the secretion of CXC chemokines/ELR+ and CC chemokines. Although TM did not modify either the M2 phenotype in the coculture or the profile of the secreted chemokines, it did decrease the angiogenic activity of the coculture medium, suggesting that TM inhibited angiogenic activity by interfering with the endothelial cell signalling induced by these chemokines.
Cooperation between Mφ and MDA-MB-231 transformed M1 Mφ to an angiogenic, M2 phenotype, attested by secretion of CXC chemokines/ELR+ and CC chemokines. TM inhibited this coculture-induced increase in angiogenic activity, without affecting either Mφ phenotype or cytokine secretion profiles.
It has become clear that analysis of tumour stroma is of crucial importance to better understanding cancer progression. Cancer cell growth and invasion of surrounding tissues, as well as the metastatic process itself, require the support of the cancer stroma.
Macrophages (Mφ) form the major component of the inflammatory infiltrate observed in tumours . They exhibit a distinct phenotype and are termed Tumour-Associated Macrophages (TAM) . Monocytes enter tumours through blood vessels, and a number of tumour-derived chemoattractants are thought to ensure this ongoing recruitment [3, 4]. This is also supported by the observation that the levels of chemoattractant proteins in tumours correlate positively with the numbers of TAMs present in these tumours . Classically, it has been accepted that fully activated Mφ have the potential to inhibit tumour development. TAMs that express an M1 phenotype are characterized by a proinflammatory cytokine profile and expression of Major Histocompatibility Complex molecules. They are capable of killing tumour cells mainly by secreting inflammatory cytokines such as Tumour Necrosis Factor α (TNFα). Although associated with better prognosis, immune responses to a tumour are often weak and not able to destroy the tumour completely , suggesting that tumours have developed mechanisms for escaping immune surveillance. Further, the presence of Mφ in breast cancer is associated with a poor prognosis [7–10] due to the role of TAMs as promoters of tumour progression and invasion. Increasing evidence also indicates that TAMs enhance angiogenesis, contributing to cancer cell proliferation and dissemination [11–14]. This could explain the positive relationship between high levels of TAMs and breast cancer aggressiveness and their correlation with high vessel density as reported in the literature [15, 16].
We have previously shown that the deleterious role of Mφ in cancer progression is due to the cooperation of monocytes with cancer cells . The modifications of Mφ functions in tumours could be explained by a switch of M1 Mφ to M2 Mφ, which have protumoral properties, including promotion of angiogenesis, matrix remodelling and suppression of adaptive immunity [18, 19]. This indicates a functional plasticity and an in situ Mφ reprogramming. The biological mechanism for this switch remains controversial. For Hagemann et al. [20, 21] and Greten et al. , the malignant epithelial cancer cells drive nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation by TAMs in a way that maintains their immunosuppressive M2 phenotype. Consequently, the blockage of NF-κB might be expected to switch the M2 Mφ to an M1 phenotype. Hence these studies would predict a potential anti-tumour effect of NF-κB inhibitors by the restoration of M1 immunity, providing a cytotoxic activity. However, the role of NF-κB in this switch is contested by others. Saccani et al.  and Bohuslav J et al.  conversely proposed that during the M1 to M2 Mφ switch, an inactivation of NF-κB occurs, explaining the absence of TNFα production when Mφ are stimulated by lipopolysaccharide (LPS). This could be due to a massive nuclear localization of the p50 NF-κB protein resulting in p50/p50 homodimers. Since the p50 homodimers lack the transactivation domain, they compete with the canonical p65/p50 heterodimers for the NF-κB binding sites on the inflammatory gene promoters, thereby blocking p65/p50 promoter binding and gene transcription.
Thus, although the relationship between inflammation and cancer aggressivity is widely accepted, many of the molecular and cellular mechanisms mediating this relationship remain unclear. The current study was designed to determine the role of the cooperation between Mφ and the aggressive breast cancer cells MDA-MB-231 in angiogenesis promotion. To elucidate the mechanism, we mimicked the inflammatory tumour environment by a coincubation of MDA-MB-231 cells with Mφ. Angiogenic activity of the coculture medium was compared with the culture medium from both MDA-MB-231 and Mφ cultured individually in the chick chorioallantoic membrane (CAM) model.
We first determined that the cooperation between Mφ and cancer cells led to a switch of M1 Mφ to the M2 phenotype, known to be angiogenic. Then we explored the potential molecular mechanisms responsible for this angiogenic activity. Results indicate that a wide repertoire of chemokines (CXC-ELR+ and CC-chemokines) may drive the neoangiogenesis induced by the cooperative effects of cancer cells and Mφ. Finally, tetrathiomolybdate (TM), an oral copper-depleting agent that has been shown to inhibit tumour-cell-induced angiogenesis [25–27] was tested in our model of cooperation between Mφ and MDA-MB-231. This was important to check because the effect of TM has not previously been analysed in this context of inflammation in cancers.
Cell Culture and Reagents
MDA-MB-231 cells were maintained in RPMI 1640 medium (Eurobio) supplemented with 100 U/ml penicillin (Eurobio), 100 μg/ml streptomycin (Eurobio), 2 mM L-glutamine (Eurobio) and 10% heat-inactivated foetal calf serum (FCS, Eurobio). All incubations were carried out in a humidified atmosphere at 37°C and 5% CO2. LPS was purchased from Sigma-Aldrich and human recombinant interferon γ (IFNγ) from R&D Systems. TM is a gift from Professor F. Sécheresse, Institut Lavoisier (CNRS UMR 8637, Versailles).
Preparation of Mφ
Human monocytes were isolated as described . Briefly, monocytes were isolated from buffy coats using lymphocyte separation medium (Eurobio). Peripheral blood mononuclear cells were washed three times with phosphate-buffered saline (PBS, Eurobio) and allowed to adhere to Primaria™ cell culture flasks (Becton Dickinson) for 1 h at 37°C. Nonadherent cells were removed. Monocytes were then incubated in AIM-V® medium (Gibco) for 7 days, as recommended for long-term cultivation of human Mφ . Medium was changed, and nonadherent cells discarded, every 2 days. We found that all monocyte-derived cells isolated this way express the marker CD14, which can be used to distinguish them from cancer cells.
Coculture of MDA-MB-231 cancer cells with Mφ
Primary human monocyte-derived Mφ were detached using a 30 min incubation with Accutase™ enzyme cell detachment medium (eBioscience). 25 × 103 MDA-MB-231 cells were plated in 96-well culture dishes (7.8 × 104 cells/cm2) and allowed to adhere for 6 h at 37°C. More than 95% of the cells adhered to the wells. Then the same number of Mφ was added, and cocultures were maintained for 5 days in RPMI 1640 medium supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 10% heat-inactivated FCS. Spent medium was replaced by fresh medium every 24 h. Control groups consisted of 2.5 × 104 MDA-MB-231 alone and of 2.5 × 104 Mφ alone cultured under the same conditions. Where indicated, after 5 days of incubation the cultures were treated with 1 μg/ml LPS and 5 ng/ml IFNγ for 24 h to activate the Mφ. Cultures approached but did not reach confluence during this time.
In vivoangiogenesis assays using the CAM model
All MDA-MB-231 and Mφ cultures were carried out both in presence and in absence of 5 μM TM (final concentration). The CAM assay was performed as described by others , using conditioned media collected from the cocultures and from individual MDA-MB-231 and Mφ cultures during the final 24 h of incubation, and stored at -80°C until use. Briefly, fertilized chick eggs (White Leghorn) purchased from the Ferme Avicole HAAS, Kaltenhouse, France, were incubated for 4 days at 37°C and a relative humidity of 80%. During this period, the eggs were positioned with the pointed end down and rotated several times. After this incubation, the shells were cracked open and the embryo eggs placed in plastic culture dishes (Merck-Eurolab) according to an established shell-less culture technique exposing the CAM to a direct access for experimental manipulation. At day 6 of embryonic development, angiogenic areas were circled with a silicon ring (Weber Métaux). To induce angiogenesis, 33 μl of either the culture medium to be tested or recombinant human basic Fibroblast Growth Factor (bFGF) (R&D Systems) (positive control) were next placed inside the rings on successive days for 3 days. Treated areas were photographed and the extent of angiogenesis evaluated 24 h after the last treatment: the total number of vessels which had sprouted from the primary vessels of the CAM and the total length of the neoangiogenesis were determined using Saisam software (Microvision Instruments).
Characterization of Mφ by immunofluorescence analysis
Cultures and cocultures were carried out as described above, except that each cell population was seeded into 8-well Lab-Tek™ II -CC2™ chambers (Nunc) at a density of 5.7 × 104 cells/cm2. Five days later, all cultures were treated with 1 μg/ml LPS and 5 ng/ml IFNγ for 24 h before washing and labelling. Mφ were identified by examining the expression of CD14, which is a differentiation antigen expressed by monocytes and Mφ, and of CD80, which is a marker of M1 Mφ . Expression of these molecules was evaluated by immunofluorescence both before and after activation with 1 μg/ml LPS and 5 ng/ml IFNγ for 24 h. Breast cancer cells were identified by cytokeratin 19 (CK 19) expression.
Briefly, cells were fixed for 15 min in 4% paraformaldehyde/PBS, then washed and incubated for 30 minutes with PBS containing 5% bovine serum albumin (BSA). For Mφ identification, samples were incubated with rabbit anti-CD14 polyclonal antibodies at 2 μg/ml (Abcam) or biotinylated monoclonal anti-human CD80 at 2.5 μg/ml (Ancell Corporation) for 60 min at room temperature. For identification of breast cancer cells, they were then washed in PBS/1% BSA before incubation with monoclonal anti-human CK 19 (Dako) diluted 1:50 in PBS/1% BSA. Following washing in PBS with 1% BSA, cells were incubated with, respectively, DyLight 488™-conjugated goat anti-rabbit IgG secondary antibody or DyLight 549™-conjugated streptavidin (Thermoscientific) for 60 minutes at room temperature or else Texas-Red labelled goat anti-mouse Ig diluted 1:2000 (AbD Serotec). After final washing, cover slips were mounted with mounting medium (Immunoconcepts). Samples were photographed using a Leica DM 5500B. Controls prepared without primary antibodies confirmed that, under the conditions used, background fluorescence was negligible.
Ability of LPS + IFNγ-activated Mφ to secrete TNFα
For these experiments, cells cultured as described above were activated on day 5 with 1 μg/ml LPS and 5 ng/ml IFNγ for 24 h. These 24-h culture supernatants were then collected and tested for TNFα. Concentrations of TNFα within the supernatants were determined by human TNFα Enzyme-Linked Immunosorbent Assay (ELISA) Ready-Set-go! (eBioscience) using the standard protocol given by the manufacturer, and compared to those of supernatants from non-activated control cultures. TNFα concentrations are expressed in pg/ml. 3 independent experiments were carried out both in presence and in absence of 5 μM TM.
Ability of Mφ to induce apoptosis in cocultures
Mφ and MDA-MB-231 cells were cultured separately and together (coculture) as indicated above for 5 days, in presence or absence of 5 μM TM. Apoptosis was measured using the ELISAPLUS cell death detection kit (Roche Diagnostics). Briefly, apoptosis-induced Desoxy-Ribonucleic Acid (DNA) fragmentation was evaluated by quantifying the histone-complexed DNA fragments (nucleosomes) found in the cytoplasm, as indicated by the manufacturer. Results are expressed as the adjusted absorbance, A405 minus A490.
Ability of Mφ to secrete interleukin 10 (IL-10)
For these experiments, supernatants were harvested on day 5 from cells cultured as described above. These 24-h culture supernatants were then tested for IL-10. Concentrations of IL-10 within the supernatants were determined by human IL-10 ELISA Ready-Set-go! (eBioscience) using the standard protocol given by the manufacturer. IL-10 concentrations are expressed in pg/ml. 3 independent experiments were carried out both in presence and in absence of 5 μM TM.
The Human Cytokine Antibody Array III kit (RayBiotech) was used to evaluate 42 different cytokines: Epithelial Neutrophil-Activating peptide-78 (ENA-78), Granulocyte Colony-Stimulating Factor (GCSF), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Growth related oncoprotein (GRO), GROα, I-309, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p40p70, IL-13, IL-15, IFNγ, Monocyte Chemotactic Protein-1 (MCP-1), MCP-2, MCP-3, Macrophage Colony Stimulating Factor (MCSF), Macrophage-Derived Chemokine (MDC), Monokine induced by IFNγ (MIG), Macrophage Inflammatory Protein-1α (MIP-1α), Regulated on Activation Normal T cell Expressed and Secreted (RANTES), human Stem Cell Factor (SCF), Stromal-Derived Factor-1 (SDF-1), Thymus and Activation-Regulated Chemokine (TARC), Transforming Growth Factor-β1 (TGF-β1), TNFα, TNF-β, Epidermal Growth Factor (EGF), Insulin-like Growth Factor-I (IGF-I), Angiogenin, Oncostatin M, Thrombopoietin, Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor-BB (PDGF BB) and Leptin. GRO detects CXC Ligand 1 (CXCL1), CXCL2 and CXCL3; GROα detects only CXCL1. VEGF detects VEGF-165 and VEGF-121.
Briefly, 1 ml of undiluted supernatants harvested on day 5 from cells cultured as described above were incubated with arrayed antibody membranes, which were then exposed to the specific biotin-antibody cocktail, following the manufacturer's instructions. Signals were detected using labelled streptavidin by exposure on X-ray films. The relative amount of each cytokine present in the coculture medium is presented as the fold increase of the spot intensity in the coculture medium as compared to that of the culture medium of either Mφ cultured alone (for cytokines which were not secreted by MDA-MB-231), or MDA-MB-231 cultured alone (for cytokines which were not secreted by Mφ), or else the sum of the two (for cytokines secreted separately by both Mφ and MDA-MB-231 when cultured individually). The area density of the spots was evaluated using imageJ (written in Java) which was downloaded from the National Centre for Biotechnology Information. Signals were normalized against the positive controls across membranes. Cytokine array experiments were carried out in duplicate.
Angiogenic activity of the Mφ + MDA-MB-231 coculture medium in the CAM
Cell densities on day 0 and after 5 days of culture (day 5)
When plating the cells on day 0, more than 95% were adherent (both cancer cells and Mφ). We next determined the relative proportions of the two cell types in the coculture after 5 days, because MDA-MB-231 is a cell line which proliferates in culture, whereas Mφ, which are primary cells, do not. We found that in 5 days the number of MDA-MB-231 increased 5.3-fold (standard error of the mean (SEM), ± 0.35) (not shown). In contrast, Mφ numbers did not change during the 5 days of incubation, and fewer than 10% were found detached, floating in the supernatants. After the 5 days of coculture, the ratio of CK 19+ (cancer cells) to Mφ was also determined. It was found that 15% of the cells were Mφ, and 85% MDA-MB-231 (not shown).
Modifications of Mφ phenotype induced by coculture
Effects of coculture on apoptotic activity, TNFα and IL-10 secretion
Molecular mechanism underlying the angiogenic activity induced by the coculture medium
Modifications of chemokines induced by coculturing Mφ with MDA-MB-231 cells
Overexpressed in coculture
ENA 78 (CXCL5)
CXC chemokine with ELR motif
- Pro-angiogenic activity
- Neutrophil chemotaxis
- Monocyte migration
- Stimulates stem cells to produce granulocytes and monocytes
- Enhances monocytic migration via RhoA and integrin activation, and via MMP expression
GRO (CXCL1, 2, 3)
CXC chemokine with ELR motif
- Angiogenic activity
- Increased migration of PBMC/monocytes
CXC chemokine with ELR motif
- Angiogenic activity
- Increased migration of PBMC/monocytes
- Inflammatory cytokine with a well-documented role in cancer
- Recruitment of myelo-monocytes
CXC chemokine with ELR motif
- Migration of neutrophils
- Important role in tumour growth, angiogenesis, and metastasis
- Anti-inflammatory cytokine
- Anti-inflammatory cytokine produced by M2 Mφ
- Recruitment of monocytes to sites of injury
- Inflammatory cytokine
- Facilitates monocyte survival, monocyte-to- Mφ conversion, Mφ proliferation, M1 to M2 switch
-Chemotactic for monocytes
Fold increase in cytokine secretion by coculture of monocytes and MDA-MB-231, as compared to the secretion by the two types of cells cultured separately
Group 1: cytokines secreted by Mφ and not by MDA-MB-231:
Ratio coculture medium/Mφ medium
Group 2: cytokines secreted by MDA-MB-231 and not by Mφ
Ratio: coculture medium/MDA-MB-231 medium
Group 3: cytokines secreted by both Mφ and MDA-MB-231
Ratio coculture/(Mφ medium cultured separately + MDA-MB-231 medium cultured separately)
Group 4: cytokines secreted only in the coculture medium
A faint spot indicating a low level of IL-10 production was also observed in the coculture medium, which corroborates the ELISA results suggesting that Mφ in the coculture acquired the M2 phenotype.
Effect of TM on the angiogenic activity induced by the coculture
As shown in Figure 1, panels A and B, TM inhibited the angiogenesis that was induced in the CAM by the coculture medium: both the total number of sprouting vessels and the cumulative length of those vessels induced by TM-containing coculture medium were similar to those measured with conditioned medium from either monocytes or MDA-MB-231 cells cultured separately in the absence of TM. The observed difference in the effects of coculturing the cells in presence versus absence of TM is highly significant.
We next analysed the mechanism by which TM inhibited the angiogenic activity of the coculture medium. Because the M2 Mφ phenotype was found to be causally implicated in the angiogenic activity of the coculture medium, we first hypothesized that TM should be able to inhibit the M1-M2 switch observed during the coculture. However, TM did not elicit a change from M2 to M1 phenotype, as shown by the following results: 1) in the coculture medium, whether in the absence or in the presence of TM, CD14+ Mφ activated by LPS/IFNγ failed to express CD80; and what's more, the expression of CD80 on Mφ cultured alone was prevented by the addition of TM to the culture medium, as shown in Figure 2A and 2B. 2) TM inhibited by 80% the secretion of TNFα in LPS/IFNγ-stimulated Mφ cultured either alone or with MDA-MB-231, suggestive of an M2 phenotype (Figure 3). Likewise, TM did not potentiate the apoptotic activity in the coculture, where the apoptosis level was equivalent to the sum of the levels seen in the individual cultures: MDA-MB-231 alone plus Mφ alone (Figure 4A and 4B). These results indicate that TM does not act by "reversing" the Mφ phenotype (M2 to M1), consistent with our observation that IL-10 secretion was increased in TM-treated Mφ (Figure 5).
Finally, we also tested the action of TM on the secretion of cytokines and chemokines that is induced by the cooperation between cancer cells and Mφ. No changes were observed when TM was added during the coculture (Figure 6, comparison between panel A without TM and panel B in the presence of TM). The ratio of cytokines secreted in the presence of TM in comparison to its absence did not vary, as the fold change was between 0.85 and 1.15.
Mφ constitute the most abundant immune cell population present in the tumour microenvironment . In many cancers, including breast cancers, it is now widely accepted that the presence of Mφ is associated with a poor prognosis. An increase in angiogenesis has been considered to be one of the major causes of the deleterious effect of Mφ in tumours. For example, the density of blood microvessels correlates with the extent of Mφ infiltration in breast cancer ; hence we hypothesized that there was a cooperation between Mφ and cancer cells to induce this angiogenic process. We therefore developed a model which mimics this cooperation by culturing Mφ in vitro with the aggressive breast cancer cells MDA-MB-231, analysed the consequences of this cooperation, and investigated the molecular mechanism mediating this angiogenic pathway. The Mφ population we tested was derived from blood monocytes and thus, at least theoretically, might be anticipated to contain some dendritic cells as well. Although we do not formally exclude this possibility, our protocol for Mφ preparation does not favour differentiation into dendritic cells. Indeed, neither the classical stimuli for dendritic cell differentiation (IL4 plus GM-CSF [32, 33]) nor more recently reported contributory agents (IFNα, TNFα, IL-15, thymic stromal lymphopoietin, Toll-like receptor ligands ) were present during the 7-day culture period used to prepare Mφ for testing. Removal of nonadherent cells during Mφ generation further disfavours dendritic cell differentiation, given that immature dendritic cells have been shown to be nonadherent cells . Moreover, MDA-MB-231 cells secrete IL-6 (Table 1), which is known to switch the differentiation of monocytes from dendritic cells to Mφ .
We found that the coculture medium induced greater angiogenic activity than did the culture medium of either Mφ or MDA-MB-231 alone in the CAM model; this enhanced angiogenic activity was evidenced by the formation of a secondary capillary network in the CAM with increases in both total number of capillaries and total length of sprouted vessels. The increased angiogenesis was still seen when coculture medium was diluted 1:2 in order to normalize for the number of cells participating in the secretion of angiogenic factors (not shown).
Next, we confirmed that the coculture of Mφ with MDA-MB-231 cells induced a switch of M1 Mφ to an M2 phenotype as shown 1) by the great reduction of CD80 expression under stimulating conditions using LPS and IFNγ on CD14 positive cells (Mφ) - the fact that LPS markedly potentiated the expression of CD80 by Mφ has also been observed by Foss et al. , 2) by the reduction of TNFα secretion by LPS + IFNγ activated Mφ, suggestive of a reduction in the number of M1 Mφ during the coculture, and 3) by the increased secretion of IL-10 into the coculture medium, pointing to a switch toward an M2 phenotype. Interestingly, this switch occurred despite the fact that, as shown by the antibody cytokine array, MDA-MB-231 cultured alone produce IL-6, which is an inflammatory cytokine (Figure 4). The M2 phenotype in our model was also characterized by its functional properties: a weak killing activity, and an increase in angiogenesis in the CAM model.
Our results are in good agreement with a number of studies showing that TAMs, which exhibit a predominantly M2-like phenotype , can elicit increased angiogenic activity. However, the molecular mechanism responsible for this angiogenic activity was not totally elucidated. To address the molecular mechanism of the angiogenesis pathway, we investigated the production of pro-inflammatory chemokines and cytokines in cocultures of MDA-MB-231 cells and Mφ, in comparison to the secretion by MDA-MB-231 or Mφ cultured separately. Our data (Figure 6 and Table 1) show that the coculture medium contains a number of potent angiogenic factors, as detected by a cytokine-antibodies array. Among the cytokines that are secreted in large amounts into the coculture medium in comparison with the culture medium of resting Mφ or of MDA-MB-231, we observed a great increase in CXC chemokines with the three amino acids (Glu-Leu-Arg/ELR) immediately amino-terminal to the CXC motif (ELR+), which are known to be pro-angiogenic . In particular, an important secretion of the GRO chemokines CXCL1/GROα, CXCL2/GROβ, CXCL3/GROγ, as well as CXCL5/ENA-78 and CXCL8/IL-8 was noted. All these chemokines play a significant role in mediating angiogenic activity during tumourigenesis in a variety of cancers [39–44] and have been shown to be of great importance in tumour progression [45, 46].
Interestingly, in addition to their angiogenic activity, it has been reported that these chemokines also play a role in monocyte recruitment in inflammation, since the blood monocytes express chemokine receptors, including CXCR2. Besides other functions, the interactions of these receptors with their chemokines induce monocyte arrest and transmigration through the endothelium, which is one of the earliest steps in monocyte recruitment, thereby efficiently regulating inflammation . Therefore our data are suggestive of an autocrine loop, because these chemokines are secreted by Mφ in cooperation with cancer cells, and they also participate in monocyte recruitment.
An increase in the proinflammatory cytokine IL-6 was also observed in the coculture medium, whereas a decrease in the secretion of this cytokine would have been expected due to the M2 phenotype of the Mφ in the coculture. This can be explained by the observation of a constitutive secretion of IL-6 by the MDA-MB-231 cells, which could be responsible for an autocrine loop for IL-6 secretion, as has been proposed for colon cancer . In other words, the observed increase in IL-6 secretion in the cocultures may be produced by the cancer cells themselves.
Our antibody array data also indicated an increase in M-CSF concentration in the coculture medium in comparison to the conditioned media from both Mφ alone and MDA-MB-231 alone. This increased secretion could elicit neovascularisation in breast cancer [5, 12] and could also contribute to the M1 to M2 switch, since M-CSF-treated monocytes express a substantial part of the M2 transcriptome .
We next investigated the effect of TM on the angiogenesis induced by the cooperation between Mφ and the MDA-MB-231 cancer cells. Several studies emphasize that TM reduces the angiogenic activity induced by tumours [52–58], which is why TM has been proposed in the therapy of cancers. However, the effect of TM has not previously been tested when cancer cells are incubated with Mφ, which represents a more physiological context: cancer associated with inflammation. We firstly demonstrated that the action of TM cannot be explained by a reversion of the angiogenic Mφ phenotype (M2 to M1), since CD80 was not detected on cells cultured in presence of TM. We also determined that the addition of TM led to a reduction of LPS/IFNγ-induced TNFα secretion (decrease of more than 80%) and an increase of IL-10 secretion in cocultured cells, and did not increase the apoptotic potential of Mφ. Pan et al.  have proposed that TM inhibits angiogenesis through suppression of the NF-κB signalling cascade. Given that TNFα secretion is NF-κB dependent, our TNFα results (Figure 3) are consistent with this interpretation, and seem to indicate that TM, like the coculture, induces a switch from M1 to M2. They also suggest that defective activation of NF-κB could lead to an M2 phenotype.
Finally, we show that, in our model, TM, which inhibits the angiogenic activity of the coculture medium, does not modify the secretion of cytokines and chemokines that is induced by the coculture. Therefore, we rather propose that TM blocks the cell signalling induced by the action of angiogenic chemokines on endothelial cells. This would be in good agreement with the studies of Donate et al.  and Juarez et al. , who showed that TM attenuates angiogenesis through the inhibition of superoxide dismutase.
In summary, based on the results and rationale presented here, we conclude that the cooperation between Mφ and the aggressive breast cancer cells MDA-MB-231 transformed M1 Mφ to an angiogenic, M2 phenotype. This coculture-induced increase in angiogenic activity, attested by an increased secretion of CXC chemokines, was found to be inhibited by TM. However, TM did not modify the cytokine secretion profile, which suggests that the TM-mediated anti-angiogenic activity may be due to defective cell signalling by these angiogenic chemokines at the level of their endothelial cell targets.
List of abbreviations used
basic Fibroblast Growth Factor
chick chorioallantoic membrane
Epidermal Growth Factor
Enzyme-Linked Immunosorbent Assay
Epithelial Neutrophil-Activating peptide 78
foetal calf serum
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony Stimulating Factor
Growth Related Oncogene
Insulin-like Growth Factor-I
Monocyte Chemotactic Protein-1
Macrophage Colony Stimulating Factor
Monokine induced by IFNγ
Macrophage Inflammatory Protein-1α
nuclear factor kappa-light-chain-enhancer of activated B cells
- PDGF BB:
Platelet-Derived Growth Factor-BB
Regulated on Activation Normal T cell Expressed and Secreted
human Stem Cell Factor
standard error of the mean
Thymus and Activation-Regulated Chemokine
Transforming Growth Factor-β1
Tumour Necrosis Factor α
Vascular Endothelial Growth Factor.
We are grateful to the comité de l'Eure de la Ligue contre le Cancer and to the Association Ti'toine, for financing the fellowship of Ulrich Joimel.
We thank the Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC) Rouen Normandie and the comité de Seine-Maritime de la Ligue contre le Cancer, who generously supported this work by a program grant from the Cancer Research Campaign.
- Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25 (3): 315-322. 10.1007/s10555-006-9001-7.View ArticlePubMedGoogle Scholar
- Gottfried E, Faust S, Fritsche J, Kunz-Schughart LA, Andreesen R, Miyake K, Kreutz M: Identification of genes expressed in tumor-associated macrophages. Immunobiology. 2003, 207 (5): 351-359. 10.1078/0171-2985-00246.View ArticlePubMedGoogle Scholar
- Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, Peck D, Darzi A: Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis. 2007, 24 (2): 121-130. 10.1007/s10585-007-9060-3.View ArticlePubMedGoogle Scholar
- Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001, 193 (6): 727-740. 10.1084/jem.193.6.727.View ArticlePubMedPubMed CentralGoogle Scholar
- Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 2001, 92 (5): 1085-1091. 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Brigati C, Noonan DM, Albini A, Benelli R: Tumors and inflammatory infiltrates: friends or foes?. Clin Exp Metastasis. 2002, 19 (3): 247-258. 10.1023/A:1015587423262.View ArticlePubMedGoogle Scholar
- Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23 (11): 549-555. 10.1016/S1471-4906(02)02302-5.View ArticlePubMedGoogle Scholar
- Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, et al: Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006, 116 (8): 2132-2141. 10.1172/JCI27648.View ArticlePubMedPubMed CentralGoogle Scholar
- Sica A, Schioppa T, Mantovani A, Allavena P: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006, 42 (6): 717-727. 10.1016/j.ejca.2006.01.003.View ArticlePubMedGoogle Scholar
- Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM: The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA. 2007, 104 (18): 7570-7575. 10.1073/pnas.0702095104.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66 (23): 11238-11246. 10.1158/0008-5472.CAN-06-1278.View ArticlePubMedGoogle Scholar
- Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000, 6 (8): 3282-3289.PubMedGoogle Scholar
- Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, et al: Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003, 88 (5): 718-725. 10.1038/sj.bjc.6600807.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S: Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005, 14 (2): 425-431.PubMedGoogle Scholar
- Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56 (20): 4625-4629.PubMedGoogle Scholar
- Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer. 2000, 85 (2): 182-188.View ArticlePubMedGoogle Scholar
- Blot E, Chen W, Vasse M, Paysant J, Denoyelle C, Pille JY, Vincent L, Vannier JP, Soria J, Soria C: Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness. Br J Cancer. 2003, 88 (8): 1207-1212. 10.1038/sj.bjc.6600872.View ArticlePubMedPubMed CentralGoogle Scholar
- Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.View ArticlePubMedGoogle Scholar
- Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci. 2008, 13: 453-461. 10.2741/2692.View ArticlePubMedGoogle Scholar
- Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005, 175 (2): 1197-1205.View ArticlePubMedGoogle Scholar
- Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR: "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008, 205 (6): 1261-1268. 10.1084/jem.20080108.View ArticlePubMedPubMed CentralGoogle Scholar
- Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004, 118 (3): 285-296. 10.1016/j.cell.2004.07.013.View ArticlePubMedGoogle Scholar
- Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A: p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66 (23): 11432-11440. 10.1158/0008-5472.CAN-06-1867.View ArticlePubMedGoogle Scholar
- Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N, Ulevitch RJ: Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest. 1998, 102 (9): 1645-1652. 10.1172/JCI3877.View ArticlePubMedPubMed CentralGoogle Scholar
- Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S: A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg. 2008, 86 (2): 383-389; discussion 390. 10.1016/j.athoracsur.2008.03.016.View ArticlePubMedGoogle Scholar
- Donate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, Smith EL, Timucin C, Braunstein MJ, Batuman OA, et al: Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer. 2008, 98 (4): 776-783. 10.1038/sj.bjc.6604226.View ArticlePubMedPubMed CentralGoogle Scholar
- Brewer GJ: Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets. 2005, 5 (3): 195-202. 10.2174/1568009053765807.View ArticlePubMedGoogle Scholar
- Von Knethen AA, Brune B: Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages. FASEB J. 2001, 15 (2): 535-544. 10.1096/fj.00-0187com.View ArticleGoogle Scholar
- Helinski EH, Bielat KL, Ovak GM, Pauly JL: Long-term cultivation of functional human macrophages in Teflon dishes with serum-free media. J Leukoc Biol. 1988, 44 (2): 111-121.PubMedGoogle Scholar
- Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M: New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res. 1997, 34 (6): 455-463. 10.1159/000159256.View ArticlePubMedGoogle Scholar
- Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM: Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008, 14 (11): 1835-1842. 10.1089/ten.tea.2007.0264.View ArticlePubMedGoogle Scholar
- Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994, 180 (1): 83-93. 10.1084/jem.180.1.83.View ArticlePubMedGoogle Scholar
- Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994, 179 (4): 1109-1118. 10.1084/jem.179.4.1109.View ArticlePubMedGoogle Scholar
- Jacobs B, Wuttke M, Papewalis C, Seissler J, Schott M: Dendritic cell subtypes and in vitro generation of dendritic cells. Horm Metab Res. 2008, 40 (2): 99-107. 10.1055/s-2007-1022561.View ArticlePubMedGoogle Scholar
- Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996, 196 (2): 137-151. 10.1016/0022-1759(96)00078-6.View ArticlePubMedGoogle Scholar
- Chomarat P, Banchereau J, Davoust J, Palucka AK: IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000, 1 (6): 510-514. 10.1038/82763.View ArticlePubMedGoogle Scholar
- Foss DL, Zilliox MJ, Murtaugh MP: Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins. Infect Immun. 1999, 67 (10): 5275-5281.PubMedPubMed CentralGoogle Scholar
- Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995, 270 (45): 27348-27357. 10.1074/jbc.270.45.27348.View ArticlePubMedGoogle Scholar
- Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996, 97 (12): 2792-2802. 10.1172/JCI118734.View ArticlePubMedPubMed CentralGoogle Scholar
- Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM: The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol. 1997, 62 (5): 554-562.PubMedGoogle Scholar
- Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM: Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest. 1998, 102 (3): 465-472. 10.1172/JCI3145.View ArticlePubMedPubMed CentralGoogle Scholar
- Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Iannettoni MD, Strieter RM: Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000, 49 (2): 63-70. 10.1007/s002620050603.View ArticlePubMedGoogle Scholar
- Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A: The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol. 2000, 67 (1): 53-62.PubMedPubMed CentralGoogle Scholar
- Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM: Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. 2004, 172 (5): 2853-2860.View ArticlePubMedGoogle Scholar
- Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL: Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol. 1995, 57 (5): 752-762.PubMedGoogle Scholar
- Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA: Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006, 42 (6): 768-778. 10.1016/j.ejca.2006.01.006.View ArticlePubMedGoogle Scholar
- Smith DF, Galkina E, Ley K, Huo Y: GRO family chemokines are specialized for monocyte arrest from flow. Am J Physiol Heart Circ Physiol. 2005, 289: (5):H1976-1984. 10.1152/ajpheart.00153.2005.View ArticlePubMedGoogle Scholar
- Lukacs NW, Hogaboam CM, Kunkel SL, Chensue SW, Burdick MD, Evanoff HL, Strieter RM: Mast cells produce ENA-78, which can function as a potent neutrophil chemoattractant during allergic airway inflammation. J Leukoc Biol. 1998, 63 (6): 746-751.PubMedGoogle Scholar
- Remedi MM, Donadio AC, Chiabrando GA: Polymorphonuclear cells stimulate the migration and metastatic potential of rat sarcoma cells. Int J Exp Pathol. 2009, 90 (1): 44-51. 10.1111/j.1365-2613.2008.00628.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY: Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol. 2009, 70 (3): 151-158. 10.1016/j.humimm.2009.01.004.View ArticlePubMedGoogle Scholar
- Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006, 177 (10): 7303-7311.View ArticlePubMedGoogle Scholar
- Pan Q, Bao LW, Merajver SD: Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res. 2003, 1 (10): 701-706.PubMedGoogle Scholar
- Sproull M, Brechbiel M, Camphausen K: Antiangiogenic therapy through copper chelation. Expert Opin Ther Targets. 2003, 7 (3): 405-409. 10.1517/14728188.8.131.525.View ArticlePubMedGoogle Scholar
- Brewer GJ, Merajver SD: Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. Integr Cancer Ther. 2002, 1 (4): 327-337. 10.1177/1534735402238185.View ArticlePubMedGoogle Scholar
- Goodman VL, Brewer GJ, Merajver SD: Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer. 2004, 11 (2): 255-263. 10.1677/erc.0.0110255.View ArticlePubMedGoogle Scholar
- Lowndes SA, Harris AL: The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia. 2005, 10 (4): 299-310. 10.1007/s10911-006-9003-7.View ArticlePubMedGoogle Scholar
- Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN: Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther. 2007, 6 (3): 1039-1045. 10.1158/1535-7163.MCT-06-0524.View ArticlePubMedGoogle Scholar
- Carpenter A, Rassam A, Jennings MH, Robinson-Jackson S, Alexander JS, Erkuran-Yilmaz C: Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells. Inflamm Res. 2007, 56 (12): 515-519. 10.1007/s00011-007-7025-2.View ArticlePubMedGoogle Scholar
- Juarez JC, Betancourt O, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Donate F: Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006, 12 (16): 4974-4982. 10.1158/1078-0432.CCR-06-0171.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/375/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.